Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain

Overview of attention for article published in Diabetes Therapy, April 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 46 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 9,242 followers.

#PublicaSalutIB Agonistes del receptor del pèptid similar al glucagó 1 en la diabetis mellitus de tipus 2 https://t.co/1fqI45oZ3t @SonEspases https://t.co/QATgLFHUDy https://t.co/u56HqiEDW0

01 Sep 2021

Reply Repost Favourite

#PublicaSalutIB Agonistas del receptor del péptido similar al glucagón 1 en la DMT2 https://t.co/7hOEWzTu4K @SonEspases https://t.co/bqtKfQUUZs https://t.co/WSnGpGDruk

25 Aug 2021

Reply Repost Favourite

#PublicaSalutIB Agonistes del receptor del pèptid similar al glucagó 1 en la diabetis mellitus de tipus 2 https://t.co/peJtqEgxMZ @SonEspases https://t.co/bqtKfQUUZs https://t.co/qgvdGFndDI

25 Aug 2021

Reply Repost Favourite

Results from a RW study in Spain suggest that patients who started treatment with #dulaglutide had higher persistence over 18 months, lower HbA1c levels at 12 months and lower annual total healthcare costs than patients who initiated other GLP-1 RA's: http

16 Apr 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.